Are there health issues with low Lp(a)?

Low Lp(a) levels are generally considered protective against cardiovascular disease and rarely cause health problems. Unlike high Lp(a), which increases heart disease risk, low levels are typically beneficial and don't require treatment.

Questions on this topic?Ask Sai, our AI longevity expert.
Ask Sai

Understanding Lp(a) and Its Role in Your Body

Lipoprotein(a), commonly abbreviated as Lp(a), is a unique type of cholesterol particle that has gained significant attention in cardiovascular medicine. Unlike other cholesterol markers that fluctuate with diet and lifestyle, Lp(a) levels are primarily determined by genetics, with about 90% of your level inherited from your parents.

Lp(a) consists of an LDL-like particle attached to a protein called apolipoprotein(a). This structure makes it particularly sticky and prone to accumulating in artery walls, which is why elevated levels are associated with increased cardiovascular risk. But what happens when your Lp(a) levels are low? Is this something to worry about?

What Are Normal and Low Lp(a) Levels?

Understanding what constitutes low Lp(a) requires knowing the typical ranges. Lp(a) is measured in either milligrams per deciliter (mg/dL) or nanomoles per liter (nmol/L), and the ranges can vary slightly between laboratories.

Lp(a) Level Categories and Health Implications

Lp(a) LevelCategoryCardiovascular RiskClinical Action
<2 mg/dL<2 mg/dL (<5 nmol/L)Very LowSignificantly reduced riskNo intervention needed
2-10 mg/dL2-10 mg/dL (5-25 nmol/L)LowReduced riskFocus on other risk factors
10-30 mg/dL10-30 mg/dL (25-75 nmol/L)NormalAverage riskStandard prevention strategies
30-50 mg/dL30-50 mg/dL (75-125 nmol/L)Borderline HighModerately increased riskEnhanced monitoring recommended
>50 mg/dL>50 mg/dL (>125 nmol/L)HighSignificantly increased riskAggressive risk factor modification

Lp(a) levels are measured once as they remain stable throughout life. Low levels provide lifelong cardiovascular protection.

  • Normal range: Less than 30 mg/dL (75 nmol/L)
  • Low levels: Less than 10 mg/dL (25 nmol/L)
  • Very low levels: Less than 2 mg/dL (5 nmol/L)
  • High risk: Greater than 50 mg/dL (125 nmol/L)

Unlike many biomarkers where both high and low levels can be problematic, Lp(a) is unique in that low levels are generally considered protective. In fact, about 20-30% of the population has very low or undetectable Lp(a) levels, and these individuals typically enjoy a lower risk of cardiovascular disease.

The Good News About Low Lp(a)

Having low Lp(a) levels is overwhelmingly positive for your cardiovascular health. Research consistently shows that people with low Lp(a) have a reduced risk of several serious conditions:

  • Coronary artery disease
  • Heart attacks
  • Stroke
  • Peripheral artery disease
  • Aortic valve stenosis

This protective effect is particularly significant because Lp(a) is not responsive to traditional cholesterol-lowering interventions like statins or lifestyle changes. While you can lower your LDL cholesterol through diet and exercise, your Lp(a) level remains relatively constant throughout life, making low levels a genetic advantage.

Cardiovascular Protection

Studies have shown that individuals with Lp(a) levels below 10 mg/dL have approximately 20-30% lower risk of developing cardiovascular disease compared to those with moderate levels. This protection appears to be independent of other risk factors like LDL cholesterol, blood pressure, and smoking status.

Reduced Inflammation

Low Lp(a) levels are associated with reduced vascular inflammation. Since Lp(a) can carry oxidized phospholipids that promote inflammation in blood vessel walls, having less of this particle means less inflammatory potential in your cardiovascular system.

Are There Any Downsides to Low Lp(a)?

The short answer is: rarely. Unlike many biomarkers that follow a U-shaped curve where both extremes are problematic, low Lp(a) levels are generally not associated with health issues. However, there are a few considerations worth noting:

Potential Associations (Not Causations)

Some studies have found weak associations between very low Lp(a) levels and certain conditions, but it's crucial to understand that these are correlations, not proven causal relationships:

  • Type 2 diabetes: Some research suggests people with type 2 diabetes tend to have lower Lp(a) levels, but low Lp(a) doesn't cause diabetes
  • Liver disease: Severe liver disease can lower Lp(a) production, but low Lp(a) itself doesn't harm the liver
  • Bleeding risk: One study suggested a slightly increased bleeding tendency, but this finding hasn't been consistently replicated

The Diabetes Connection

The relationship between Lp(a) and diabetes is complex and somewhat paradoxical. While low Lp(a) protects against cardiovascular disease, some studies have found that people with type 2 diabetes often have lower Lp(a) levels than non-diabetics. This doesn't mean low Lp(a) causes diabetes; rather, the metabolic changes associated with diabetes may affect Lp(a) production.

Who Should Test Their Lp(a) Levels?

Since Lp(a) levels are genetically determined and remain stable throughout life, you typically only need to test once. However, certain individuals should prioritize getting tested:

  • Family history of premature heart disease (before age 55 in men, 65 in women)
  • Personal history of heart disease with normal or controlled traditional risk factors
  • Family members with known elevated Lp(a)
  • Recurrent cardiovascular events despite statin therapy
  • Family history of aortic valve disease

Understanding your Lp(a) level provides valuable information about your cardiovascular risk profile. If you discover you have low levels, consider it a protective factor that works in your favor. For comprehensive cardiovascular health monitoring, including Lp(a) testing, regular biomarker assessment can help you track all aspects of your heart health.

Managing Your Overall Cardiovascular Risk

While low Lp(a) is protective, it doesn't make you immune to cardiovascular disease. Other risk factors still matter significantly:

Traditional Risk Factors to Monitor

  • LDL cholesterol (aim for less than 100 mg/dL, or less than 70 mg/dL if high risk)
  • HDL cholesterol (aim for greater than 40 mg/dL in men, 50 mg/dL in women)
  • Triglycerides (aim for less than 150 mg/dL)
  • Blood pressure (aim for less than 120/80 mmHg)
  • Fasting glucose and HbA1c
  • Inflammatory markers like high-sensitivity CRP

Lifestyle Factors

Even with the advantage of low Lp(a), maintaining heart-healthy habits remains crucial:

  • Regular physical activity (at least 150 minutes of moderate exercise weekly)
  • Mediterranean-style diet rich in vegetables, fruits, whole grains, and healthy fats
  • Maintaining a healthy weight
  • Not smoking
  • Managing stress effectively
  • Getting adequate sleep (7-9 hours nightly)

Special Considerations for Different Populations

Lp(a) levels can vary significantly between ethnic groups, with some populations naturally having higher or lower average levels:

  • African ancestry: Tend to have higher Lp(a) levels on average
  • South Asian ancestry: Often have moderately elevated levels
  • East Asian ancestry: Generally have lower levels
  • European ancestry: Wide variation, but many have low to moderate levels

These ethnic variations don't change the interpretation that low levels are protective, but they do highlight why personalized testing is important rather than assuming risk based on population averages.

The Future of Lp(a) Research

While low Lp(a) levels are clearly beneficial, research continues to explore this biomarker's full role in health and disease. Current areas of investigation include:

  • Development of Lp(a)-lowering medications for those with high levels
  • Understanding the genetic variants that determine Lp(a) levels
  • Exploring whether Lp(a) has any beneficial functions in the body
  • Investigating the interaction between Lp(a) and other cardiovascular risk factors

Taking Action: What Low Lp(a) Means for You

If you've tested and found you have low Lp(a) levels, here's what it means for your health strategy:

  1. Consider it a cardiovascular protective factor in your overall risk assessment
  2. Don't neglect other modifiable risk factors - they still matter
  3. Share this information with family members, as they may have similar levels
  4. Include this data when discussing cardiovascular prevention with your healthcare provider
  5. Continue regular health monitoring to track other important biomarkers

Low Lp(a) levels represent one of the few instances in medicine where having less of something is almost universally better. Unlike many biomarkers that require careful balance, Lp(a) follows a simple rule: lower is better for cardiovascular health. While you can't change your Lp(a) levels through lifestyle modifications, knowing your status helps you and your healthcare provider make more informed decisions about your overall cardiovascular disease prevention strategy.

Remember that cardiovascular health is multifaceted. Even with the advantage of low Lp(a), maintaining healthy lifestyle habits and monitoring other risk factors remains essential for optimal heart health throughout your life.

References

  1. Tsimikas, S. (2017). A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69(6), 692-711.[Link][DOI]
  2. Kronenberg, F., & Utermann, G. (2013). Lipoprotein(a): resurrected by genetics. Journal of Internal Medicine, 273(1), 6-30.[Link][DOI]
  3. Nordestgaard, B. G., & Langsted, A. (2016). Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. Journal of Lipid Research, 57(11), 1953-1975.[Link][DOI]
  4. Paré, G., et al. (2019). Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation, 139(12), 1472-1482.[Link][DOI]
  5. Mora, S., et al. (2018). Lipoprotein(a) and risk of type 2 diabetes. Clinical Chemistry, 64(8), 1183-1191.[Link][DOI]
  6. Reyes-Soffer, G., et al. (2022). Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 42(1), e48-e60.[Link][DOI]

Was this article helpful?

Frequently Asked Questions

How can I test my Lp(a) at home?

You can test your Lp(a) at home with SiPhox Health's Heart & Metabolic Program, which includes Lp(a) testing along with other crucial cardiovascular biomarkers. This CLIA-certified program provides lab-quality results from the comfort of your home.

What is considered a low Lp(a) level?

Low Lp(a) levels are typically below 10 mg/dL (25 nmol/L), with very low levels being under 2 mg/dL (5 nmol/L). These low levels are associated with reduced cardiovascular disease risk and are generally considered protective.

Can I increase my Lp(a) levels if they're too low?

There's no need to increase low Lp(a) levels, as they're protective against heart disease. Unlike other cholesterol markers, Lp(a) is genetically determined and doesn't respond to diet or lifestyle changes. Low levels are beneficial, not harmful.

How often should I test my Lp(a) levels?

Since Lp(a) levels are genetically determined and remain stable throughout life, you typically only need to test once. However, if you have other cardiovascular risk factors, regular monitoring of your complete lipid panel every 3-6 months can help track your overall heart health.

Is there a connection between low Lp(a) and diabetes?

Some studies show that people with type 2 diabetes tend to have lower Lp(a) levels, but low Lp(a) doesn't cause diabetes. The metabolic changes in diabetes may affect Lp(a) production, but having low Lp(a) remains protective for cardiovascular health even in people with diabetes.

This article is licensed under CC BY 4.0. You are free to share and adapt this material with attribution.

Ask Questions About Any Health Topic

Chat with Sai, our AI health assistant, for personalized insights.

Click or drag file to upload blood test results

Backed By Leading Experts in Health Optimization

Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details